Infantile Spasms Therapeutics Market
Report ID: SQMIG35I2371
Report ID: SQMIG35I2371
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35I2371 |
Region:
Global |
Published Date: May, 2025
Pages:
191
|Tables:
143
|Figures:
75
Global Infantile Spasms Therapeutics Market size was valued at USD 149.24 Million in 2024 and is poised to grow from USD 159.09 Million in 2025 to USD 265.28 Million by 2033, growing at a CAGR of 6.6% during the forecast period (2026–2033).
Growing incidence of infantile spasms, rising awareness regarding pediatric diseases, government support for R&D, advancements in drug formulations, and expansion of pediatric neurology infrastructure are helping promote the adoption of infantile spasms therapeutics.
Increasing cases of infantile spasms, especially in developed and developing countries is primarily augmenting the global infantile spasms therapeutics market growth. Growing awareness among pediatricians, advancements in drug formulations, and high investments in pediatric neurology R&D are also helping boost revenue generation. Expansion of specialized pediatric neurology around the world is also improving accessibility to infantile spasms therapeutics. The emergence of advanced EEG, MRI, and genetic sequencing tools has revolutionized early diagnosis of infantile spasms. Government healthcare programs and nonprofit organizations worldwide are raising awareness and funding for rare childhood neurological disorders.
On the contrary, high costs of treatment, limited availability of trained specialists, side effects of current therapies, and underdiagnosis in developing countries are slated to impede the global infantile spasms therapeutics sales across the forecast period and beyond.
Market snapshot - 2026-2033
Global Market Size
USD 140.0 million
Largest Segment
Liquid
Fastest Growth
Solid
Growth Rate
6.6% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The liquid segment is forecasted to account for a substantial chunk of the global infantile spasm’s therapeutics market share. Quick absorption of liquid therapeutics and faster show of effect on patients are key benefits of liquid dosage helping the dominance of this segment. Infants are more accepting of liquid dosage of therapeutics as capsules and tablets might be hard for them to swallow.
On the other hand, the solid dosage segment is slated to hold the second-largest share of the global infantile spasms therapeutics industry. Controlled release and fewer side effects of solid dosage form are expected to help promote market development via this segment in the long run.
Hospital pharmacies are expected to hold the largest share of the global infantile spasms therapeutics market revenue in the future. High convenience offered by hospital pharmacies makes it a preferred choice for the purchase and sales of infantile spasms therapeutics. Availability of a controlled and specialized environment for dispensing medications like vigabatrin, ACTH, or corticosteroids in hospital pharmacies is further cementing the dominance of this segment.
Meanwhile, the demand for infantile spasms therapeutics via online pharmacies is slated to rise at an impressive CAGR over the coming years. Growing preference for online shopping and rising number of online pharmacies are helping improve accessibility to infantile spasms therapeutics.
To get detailed segments analysis, Request a Free Sample Report
North America dominates the global infantile spasms therapeutics industry due to strong healthcare infrastructure, high awareness among clinicians and parents, and access to advanced treatments. High availability of robust reimbursement policies and FDA-approved therapies like ACTH and vigabatrin are also cementing the dominance of this region. Ongoing investments in drug discovery and supportive government initiatives are also expanding the business scope of companies.
Early diagnosis capabilities, presence of FDA-approved therapies (like ACTH and vigabatrin), and high awareness among healthcare providers help this country emerge as a leader in North America. Presence of a robust reimbursement infrastructure and orphan drug incentives supporting high-cost treatments also promote infantile spasms therapeutics uptake. The presence of leading biopharma companies, academic hospitals, and advocacy groups further cements the dominance of the United States.
Efforts to standardize care pathways, national awareness campaigns and newborn screening programs are expected to boost sales of infantile spasms therapeutics in Canada through 2032. Canada's participation in global research trials and alignment with FDA/EMA guidelines make it a highly rewarding country in the North American region after the United States. Specialized pediatric neurology centers, especially in Ontario and British Columbia, offer ACTH, vigabatrin, and steroid therapy.
Asia Pacific is witnessing rapid growth in demand for infantile spasms therapeutics due to improving healthcare access, rising awareness, and increasing incidence of epilepsy in infants. Government-backed neonatal screening programs and expanded insurance coverage are also estimated to offer new opportunities in the future. Healthcare digitization is also predicted to increase accessibility to infantile spasms therapeutics.
Presence of an advanced medical system supports strong early detection and treatment of infantile spasms. Japan emphasizes genetic testing and neuroimaging in pediatric care. Pharmaceutical firms like Eisai are investing in pediatric neurology pipelines. Cultural emphasis on proactive child health management and early treatment uptake are also expected to bolster the sales of infantile spasms therapeutics in Japan through 2032.
Coverage of key therapeutics, including ACTH and steroid-based regimens by national health insurance is helping South Korea emerge as a rewarding country. Growing awareness among general pediatricians, coupled with strong parental involvement is also estimated to favor the adoption of infantile spasms therapeutics going forward. South Korea is also emerging as a regional clinical trial hub for pediatric neurological disorders, which further expands its business scope.
Adoption of advanced diagnostic tools, universal healthcare systems, and the availability of established treatment protocols are making Europe a rewarding region. Increased emphasis on genetic testing is driving up the demand for precision treatment thereby also favoring the adoption of infantile spasms therapeutics in this region. Public health initiatives and clinical registries are also expected to help create a new business scope for infantile spasms therapeutics providers.
NHS (National Health Service) and its network of pediatric epilepsy specialists are supporting infantile spasms management in the United Kingdom. Research institutions like Great Ormond Street Hospital and collaborations with the Epilepsy Research Institute are advancing therapeutics and clinical trials. National awareness campaigns, support groups, and electronic health records are also slated to indirectly influence infantile spasms therapeutics adoption in the United Kingdom.
Germany leads in Europe’s infantile spasms therapeutics space due to its well-organized healthcare infrastructure and strong pediatric neurology networks. Children’s hospitals offer early EEG testing and access to therapies like vigabatrin and ACTH. Public insurance covers major treatments, and medical societies actively disseminate guidelines. Patient registries and medical databases enable data-driven treatment planning, making Germany a key European center for advanced diagnostics and therapeutics in pediatric epilepsy.
France provides robust support for infantile spasms care through its universal healthcare model and a dense network of pediatric neurologists. Early intervention programs, public awareness campaigns, and support from agencies like Inserm (National Institute of Health and Medical Research) improve outcomes. Government funding for rare neurological disorders and collaboration with pharma companies are fostering drug development.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increased Awareness Among Pediatricians
Advancements in Drug Formulations
Side Effects and Risks of Current Therapies
Limited Availability of Trained Specialists
Request Free Customization of this report to help us to meet your business objectives.
Infantile spasms therapeutics providers should focus on advancing gene therapies to maximize their business scope. Gaining approvals for novel therapies and drugs for the treatment of infantile spasms at different levels is also a key area of interest for companies. Reducing the side effects of treatments and therapeutics is also a key opportunity for companies as per this global infantile spasm’s therapeutics market analysis.
Investing in new gene therapies and focusing on advancing gene technologies to treat rare diseases remains the prime focus of startups. Here are some startups that are working on treating infantile spasms to help improve overall child care.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing incidence of infantile spasms around the world and advancements in drug formulations are anticipated to drive the demand for infantile spasms therapeutics going forward. However, limited availability of trained specialists and risk of side effects of current therapies are slated to slow down the sales of infantile spasms therapeutics in the future. North America is slated to spearhead the demand for infantile spasms therapeutics owing to presence of a developed healthcare infrastructure and robust reimbursement policies. Emphasis on early detection and adoption of precision medicine are anticipated to be key trends driving the infantile spasms therapeutics industry through 2032 and beyond.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 149.24 Million |
| Market size value in 2033 | USD 265.28 Million |
| Growth Rate | 6.6% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Infantile Spasms Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Infantile Spasms Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Infantile Spasms Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Infantile Spasms Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
